Yüksel Ürün· @DrYukselUrun · X·· 23 hours agoScore70
Body · original
Another reminder that immunotherapy is not a universal solution.
KEYNOTE-B49 highlights the need for better patient selection.
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26
269 views · 9 likes · 4 reposts · 1 reply
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgKeynote B49 - pembrolizumab does not work much in this Hr positive Her2 negative MBC population( endocrine resistant ) @myESMO @dr_yakupergun @OncoAlert #esmo26在 X 查看被引用的帖子
Replies in this thread
- Michiel Strijbos@StrijbosMichiel
@DrYukselUrun @mirrorsmed @myESMO @OncoAlert @OpenMedicineHQ Not every tumor’s a superhero waiting for its IO cape… but with the right biomarker sidekick, we still get some cape-worthy wins! 🦸♂️🔬✨ #SelectWisely #KEYNOTEB49
Source: Yüksel Ürün · x.com